Reviva Pharmaceuticals Holdings (RVPH) Change in Account Payables (2018 - 2026)

Reviva Pharmaceuticals Holdings has reported Change in Account Payables for 9 years, with the latest figure at -$976347.0 in Q1 2026.

• Quarterly Change in Account Payables rose 37.51% year-over-year to -$976347.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.8 million (down 146.97% YoY) and the FY2025 annual result came in at -$3.4 million, down 248.73% from the prior year.
• Change in Account Payables improved to -$976347.0 in Q1 2026 per RVPH's latest filing, from -$2.2 million in the prior quarter.
• Over five years, Change in Account Payables peaked at $4.1 million in Q3 2024 and troughed at -$2.6 million in Q4 2024.
• A 5-year average of $73328.9 and a median of -$212291.0 in 2023 frame the typical range for Change in Account Payables.
• The sharpest annual moves came in 2022 and 2023: Change in Account Payables slumped 489.7% in 2022, then soared 1179.38% in 2023.
• Over 5 years, Change in Account Payables stood at $1.4 million in 2022, then tumbled by 203.57% to -$1.4 million in 2023, then plunged by 84.52% to -$2.6 million in 2024, then rose by 16.69% to -$2.2 million in 2025, then jumped by 55.56% to -$976347.0 in 2026.
• According to Business Quant data, Change in Account Payables over the past three periods registered -$976347.0, -$2.2 million, and $325332.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.